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Hodgkin’s lymphoma in adults
William Townsend, David Linch
Management of Hodgkin’s lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage 
disease are excellent, and serial reductions in intensity of treatment have been made to retain the excellent prognosis 
while reducing the late eﬀ ects of treatment. Prognosis is also very good in advanced-stage disease but the rate of 
relapse is higher than in early-stage disease, and the optimum ﬁ rst-line treatment is unclear. Workers are investigating 
the role of functional imaging to assess whether treatment can be tailored according to response, with the most 
intensive therapies reserved for patients predicted to have poor outcomes. In this Seminar we critically appraise the 
management of Hodgkin’s lymphoma in early-stage disease, advanced-stage disease, and at relapse, with a focus on 
late eﬀ ects of treatment.
Introduction
Most patients with Hodgkin’s lymphoma are cured with 
ﬁ rst-line therapy. The main challenges are to reduce the 
toxic eﬀ ects of treatment while maintaining excellent 
outcomes, and to improve survival for patients with 
poor-risk, refractory, or relapsed disease. Since our 
previous Seminar,1 there have been important advances 
in the management of Hodgkin’s lymphoma, most 
notably in the use of PET, deintensiﬁ cation of treatment 
in selected patients, and the management of relapsed 
disease.
Epidemiology
Incidence of Hodgkin’s lymphoma in the UK and USA is 
2·7–2·8 per 100 000 per year, with roughly 1700 new 
cases diagnosed in the UK every year.2,3 The disease is 
more frequent in men than in women, and peaks in 
incidence are noted in young adults and in people 
older than 60 years.4,5 Incidence has remained mostly 
unchanged during the past two decades.6,7 Hodgkin’s 
lymphoma is classiﬁ ed as either classical or nodular 
lymphocyte-predominant.8 Four subtypes of classical 
Hodgkin’s lymphoma exist, which diﬀ er in presentation, 
sites of involvement, epidemiology, and association with 
Epstein-Barr virus (table 1); management, however, is 
broadly similar in all subtypes.8 Nodular lymphocyte-
predominant Hodgkin’s lymphoma has a distinct 
histological appearance, immunophenotype, and clinical 
course. Understanding of the pathophysiology of 
Hodgkin’s lymphoma continues to develop.9–11
Diagnosis and staging
Hodgkin’s lymphoma typically presents as painless 
lymphadenopathy, which is frequently cervical or supra-
clavicular. More than 50% of patients have a mediastinal 
mass, which can be asymptomatic or can present as 
dyspnoea, cough, or obstruction of the superior vena 
cava.12 Systemic symptoms are reported in 25% of 
patients. Fever, drenching night sweats, and loss of more 
than 10% of bodyweight over 6 months are termed 
B symptoms and have prognostic importance. Other 
symptoms such as pruritis, fatigue, and alcohol-related 
pain do not have prognostic importance and are thus 
not regarded as B symptoms. Diagnosis of Hodgkin’s 
lymphoma should be conﬁ rmed histologically. Contrast-
enhanced CT of the neck, chest, abdomen, and pelvis 
should be done for staging. Functional imaging with 
¹⁸F-ﬂ uorodeoxyglucose (¹⁸F-FDG) PET is increasingly 
used to stage disease accurately, delineate margins of 
radiotherapy, and provide a baseline for subsequent 
response assessment.
Bone-marrow involvement is identiﬁ ed in 5–8% of 
patients with Hodgkin’s lymphoma, but in apparently 
early-stage disease the rate of involvement is less than 1% 
and is generally judged too low to justify taking of a bone 
marrow biopsy.13–15 In advanced disease, discovery of bone-
marrow involvement will not change treatment, but will 
aﬀ ect the restaging procedures done at the end of treat-
ment. ¹⁸F-FDG PET is sensitive for focal bone-marrow 
inﬁ ltration,16 and its increasing use will reduce the number 
of staging trephine biopsies done. Staging of Hodgkin’s 
lymphoma is based on modiﬁ cations of the Ann Arbor 
system (panel 1), and is useful for prognostication and 
treatment planning.
Prognosis and risk stratiﬁ cation
The outlook for patients with early-stage disease (stage 
I–IIA) is excellent, with overall survival exceeding 90% in 
many trials. In advanced-stage disease, overall survival is 
75–90%. In both early-stage and advanced-stage disease, 
further stratiﬁ cation according to risk factors is often 
done. Early-stage disease is stratiﬁ ed into favourable and 
unfavourable (sometimes referred to as intermediate 
stage) by some groups according to the presence or 
absence of risk factors. The deﬁ nition of early-stage 
Search strategy and selection criteria
We systematically searched Medline and PubMed for 
articles published between January, 2000 and July, 2012 for 
the term “Hodgkin’s lymphoma” and the related terms 
“early stage”, “advanced stage”, and “relapsed” or 
“refractory”. We did not restrict references by language of 
publication, and relevant references published before the 
search period were also included. References from relevant 
articles were also searched. Conference reports and 
abstracts are included when relevant. 
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unfavourable disease varies (table 2), but the most 
consistently used determinants are disease bulk and the 
presence of B symptoms. In the UK and the USA, 
subdivision of early-stage disease is not common 
practice; instead patients with B symptoms are judged to 
have advanced disease. However, evidence shows that 
profound treatment reductions can be made in favourable 
early-stage disease,17 and thus identiﬁ cation of this group 
of patients should be mandatory.
For advanced stage disease, the international prog-
nostic score (also known as the Hasenclever score) is 
used to predict prognosis.18 The score is calculated 
according to seven clinical and laboratory factors 
(panel 2); the presence of each factor reduces 5 year 
overall survival on average by 8% (table 3). Risk 
stratiﬁ cation according to response assessment by 
interim ¹⁸F-FDG PET in both early-stage and advanced-
stage disease will probably supplement or replace 
present methods of assigning risk.
PET in Hodgkin’s lymphoma
¹⁸F-FDG PET can be used in combination with CT for 
staging, end-of-treatment and interim assessments, and 
follow-up surveillance, although its precise role has not 
been deﬁ ned. In prospective studies, ¹⁸F-FDG PET at 
diagnosis upstaged 13–24% more patients than did CT.19–21 
When upstaging moves a patient from early-stage to 
advanced-stage disease (as happened in 7–15% of 
patients), a change in management is warranted.19–21 
There is no evidence that this change in management 
aﬀ ects long-term survival, however, partly because of the 
success of salvage therapy. Staging ¹⁸F-FDG PET also 
provides a baseline scan against which subsequent scans 
can be compared.22
End-of-treatment ¹⁸F-FDG PET can be used to 
distinguish between ﬁ brotic tissue and residual active 
disease. In a prospective study,23 negative end-of-
treatment ¹⁸F-FDG PET had a 96% (95% CI 91–97) 
negative predictive value for progression or early relapse 
in advanced-stage disease. Thus, in advanced-stage 
patients with a residual mass but a negative end-of-
treatment ¹⁸F-FDG PET scan, radiotherapy could 
potentially be omitted. ¹⁸F-FDG PET has been adopted 
in the revised response criteria for lymphoma, which 
require a negative scan to classify a patient as in 
complete remission and allows residual masses as long 
as they are not ¹⁸F-FDG avid—so-called metabolic 
complete remission.22 Although the negative predictive 
value of ¹⁸F-FDG PET is very high, the positive predictive 
value is less reliable, with false-positives occurring 
because of infection, inﬂ ammation, increased uptake of 
¹⁸F-FDG in brown fat, and reactive changes after 
treatment. Thus, to ascertain whether relapse has 
occurred, histological evidence is preferable to ¹⁸F-FDG 
PET alone.24
The greatest interest is in the potential use of ¹⁸F-FDG 
PET for interim assessment after initial cycles of 
chemotherapy, with the aim of identiﬁ cation of which 
patients are cured and which need escalation of 
treatment. Response after two cycles of chemotherapy is 
more predictive of outcome than traditional risk 
stratiﬁ cation based on results of clinical and laboratory 
tests.25–27 Data suggest that interim assessment can be 
even more predictive if done after the ﬁ rst cycle of 
chemotherapy.28 Results of prospective clinical trials 
assessing the escalation or de-escalation of treatment on 
the basis of interim ¹⁸F-FDG PET are awaited. Until 
conclusive results are available, treatment decisions 
should not be made by interim assessment. Surveillance 
¹⁸F-FDG PET has been assessed in routine follow-up, but 
data do not support such an approach.29
There are several unresolved questions relating to the 
reproducibility and quality control of ¹⁸F-FDG PET and 
the standardised interpretation of minimum uptake. 
Quantiﬁ cation of ¹⁸F-FDG uptake can be assessed as a 
standard uptake value or by visual assessment. For the 
purposes of clinical trials, a ﬁ ve-point scale (Deauville 
scale) that compares the standard uptake value of a lesion 
with that of the mediastinum or liver is recommended 
(panel 3).30
EBV association Epidemiology Clinical features 
Nodular lymphocyte-predominant 
Hodgkin’s lymphoma
No association Accounts for 5% of all Hodgkin’s lymphoma; more 
common in male than in female patients
75% of patients are early stage; risk of transformation to 
high-grade non-Hodgkin lymphoma
Classical Hodgkin’s lymphoma
Nodular sclerosis classical 
Hodgkin’s lymphoma
Intermediate association; 
10–40% of patients EBV positive
Accounts for 70% of classical Hodgkin’s lymphoma in 
Europe and North America
Mediastinal mass present in 80% of patients; prognosis 
better than in other subtypes of classical disease
Mixed-cellularity classical 
Hodgkin’s lymphoma
Strong association; up to 75% of 
patients EBV positive
Accounts for 25% of classical disease; prevalent in 
patients with HIV infection and developing countries
Peripheral and abdominal lymphadenopathy common; 
splenic inﬁ ltration in 30% of patients
Lymphocyte-rich classical 
Hodgkin’s lymphoma
Intermediate association Accounts for 5% of classical Hodgkin’s lymphoma Peripheral lymphadenopathy common; mediastinal mass rare
Lymphocyte-depleted classical 
Hodgkin’s lymphoma
Strong association; up to 75% of 
patients EBV positive
Rarest subtype, accounts for <1% of cases in Europe and 
North America; prevalent in patients with HIV infection 
and developing countries
Patients frequently present with advanced-stage disease
EBV=Epstein-Barr virus.
Table 1: Subtypes of Hodgkin’s lymphoma, association with Epstein-Barr virus, epidemiology, and clinical features8
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Management
Early-stage favourable disease
Combined modality therapy (chemotherapy and radio-
therapy) has replaced radiotherapy alone in localised 
Hodgkin’s lymphoma because it substantially reduces 
relapse rate through the chemotherapeutic eradication of 
occult disease outside the radiation ﬁ eld and allows for 
smaller radiation ﬁ elds.31–34 A meta-analysis35 conﬁ rmed a 
reduction in relapse rate with combined modality therapy, 
and although it did not report a survival beneﬁ t, a separate 
retrospective study36 identiﬁ ed mantle ﬁ eld radiotherapy 
alone as an independent risk factor for death.
The gold-standard treatment for favourable early-
stage disease was thought to be four cycles of ABVD 
(doxorubicin, bleomycin, vinblastine, and dacarbazine) 
followed by 36 Gy involved-ﬁ eld radiotherapy (IFRT),37 
but this approach now represents over-treatment. The 
European Organisation for Research and Treatment of 
Cancer (EORTC) H9 trial38 suggested that the radiation 
dose could be reduced to 20 Gy in patients who achieved 
complete remission or complete remission unconﬁ rmed 
after chemotherapy. The German Hodgkin Lymphoma 
Study Group (GHSG) HD10 trial17 randomly assigned 
patients with favourable early-stage disease to two or four 
cycles of ABVD chemotherapy followed by either 20 Gy 
or 30 Gy IFRT. At 5 year follow-up, investigators reported 
no signiﬁ cant diﬀ erence in freedom from treatment 
failure or overall survival between the study groups, and 
more toxic eﬀ ects in the groups that received four cycles 
of chemotherapy or 30 Gy IFRT, or both. Two cycles of 
ABVD and 20 Gy IFRT should therefore be regarded as 
the standard of care in favourable early-stage disease as 
deﬁ ned by the GHSG (ie, <three sites of disease without 
bulk, extranodal extension, or raised ESR; table 2), with 
an event-free survival of 91% and an overall survival of 
93% at 5 years.
Trials investigating whether radiotherapy can be 
omitted have also been done,38–40 and a Cochrane review41 
reported that combined modality therapy was associated 
with improvements in both progression-free survival 
(hazard ratio [HR] 0·41, 95% CI 0·25–0·66) and overall 
survival (0·40, 0·27–0·59), although a more recent 
investigation42 that used outmoded, extensive radiotherapy 
ﬁ elds suggested that ABVD alone was superior in the 
long term to sub-total nodal irradiation with or without 
ABVD. Concerns about the late eﬀ ects of radiotherapy 
(especially the increased risk of secondary malignancies) 
have led some groups to recommend chemotherapy 
alone in carefully selected patients with early-stage 
disease when the risk of secondary malignancies is 
deemed high. Such patients might include women 
younger than 35 years or those who have a family history 
of breast cancer for whom the radiation ﬁ eld would 
incorporate breast tissue.43,44 Trials45,46 in early-stage disease 
(some of which are expected to report in 2013) are 
assessing whether interim ¹⁸F-FDG PET can be used to 
identify patients who do not need radiotherapy.
Attempts have also been made to reduce the intensity of 
chemotherapy cycles. The GHSG HD13 trial47 compared 
four diﬀ erent variations of ABVD combined with 30 Gy 
IFRT to establish whether bleomycin and dacarbazine 
can be omitted. More relapses were reported when either 
dacarbazine or both dacarbazine and bleomycin were 
omitted than in patients who received standard treatment, 
leading to early closure of these groups. The ﬁ nal analysis 
will investigate the omission of bleomycin, which would 
Panel 1: Ann Arbor staging system and Cotswold 
modiﬁ cations for Hodgkin’s lymphoma
Stage
I Involvement of one lymph-node region or lymphoid 
structure
II Involvement of two or more lymph-node regions on the 
same side of the diaphragm
III Involvement of lymph nodes on both sides of the 
diaphragm
1 Splenic hilar, coeliac, or portal nodes
2 Para-aortic, iliac, or mesenteric nodes
IV Involvement of extranodal sites other than one 
contiguous or proximal extranodal site
Modifying features
A No symptoms
B Presence of fever, drenching night sweats, loss of more 
than 10% of bodyweight over 6 months
X Bulky disease (mediastinal mass larger than a third of 
thoracic diameter, or any nodal mass >10 cm in diameter)
E Involvement of one contiguous or proximal extranodal site
Risk factors Stratiﬁ cation
GHSG (Germany) ≥3 nodal areas involved, mediastinal bulk*, 
ESR ≥50 or ESR ≥30 if B symptoms present†, 
extranodal disease
Favourable=stage I–II with no risk factors;
unfavourable (intermediate)=stage I–IIA 
with ≥1 risk factor, or stage IIB with no 
mediastinal bulk or extranodal disease
EORTC‡ Age ≥50,mediastinal bulk, ESR ≥50 or ESR 
≥30 if B symptoms present, ≥4 nodal sites
Favourable=stage I–II supradiaphragmatic 
disease with no adverse factors; 
unfavourable=stage I–II supradiaphragmatic 
disease with ≥1 risk factor
GELA (France) Any increase in ESR, age ≥45 years,
extranodal disease, haemoglobin ≤105 g/L, 
lymphocyte count ≤0·6×10⁹/L, male sex
Favourable=stage I–II with no risk factors; 
unfavourable=stage I–IIA with ≥1 risk factor
ECOG/NCI (USA) Bulky disease§, B symptoms Early stage=no adverse factors; advanced 
stage=≥1 risk factor
NCRI (UK) Bulky disease§, B symptoms Early stage=no adverse factors; advanced 
stage=≥1 risk factor
The country in which the research group is based is shown in parentheses. GHSG=German Hodgkin Study Group. 
EORTC=European Organisation for Research and Treatment of Cancer. GELA=Groupe d’Etudes des Lymphomes 
de l’Adulte. ECOG=Eastern Cooperative Oncology Group. NCI=National Cancer Institute. NCRI=National Cancer 
Research Institute. *Mediastinal bulk is deﬁ ned as a mediastinal mass with a diameter greater than 0·35 times the 
maximum thoracic diameter. †B Symptoms are unexplained fever, night sweats, or documented unexplained weight 
loss (>10% bodyweight over 6 months). ‡EORTC early-stage favourable trials do not include very favourable patients— 
ie, patients with stage IA disease, patients younger than 40 years, or female patients with nodular sclerosing histology. 
§Bulky disease includes mediastinal mass larger than 0·35 times the transthoracic diameter, and other sites of disease 
measuring 10 cm or larger.
Table 2: Risk stratiﬁ cation of early-stage Hodgkin’s lymphoma, by research group
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be advantageous in view of the drug’s association with 
pulmonary ﬁ brosis.
Early-stage unfavourable disease
Combined modality therapy is the standard treatment for 
unfavourable early-stage disease in most of Europe, 
although most patients with B symptoms or bulky 
disease in the UK have been treated with protocols used 
for advanced disease. In the EORTC H8 trial,32 IFRT was 
as eﬀ ective as extended-ﬁ eld radiotherapy (EFRT) in early 
unfavourable disease and no diﬀ erence in outcome  was 
reported between four and six cycles of MOPP–ABV 
(mechlorethamine, vincristine, procarbazine, prednis-
olone, doxorubicin, bleomycin, and vinblastine).32 The 
GHSG HD8 trial showed that after four cycles of 
alternating COPP (cyclophosphamide, vincristine, pro-
carbazine, and prednisolone) and ABVD, relapse rate or 
survival did not diﬀ er between the IFRT (30 Gy and an 
additional 10 Gy to sites of bulk) and EFRT (30 Gy and an 
additional 10 Gy to sites of bulk) groups, although acute 
toxic eﬀ ects were signiﬁ cantly higher in the latter.48 
Although these protocols resulted in high rates of 
complete remission, relapse rates of up to 15–20% have 
led to searches for more eﬀ ective initial chemotherapy.49
The EORTC H9 trial50 randomly assigned patients with 
early unfavourable disease to four cycles of ABVD, six 
cycles of ABVD, or four cycles of baseline BEACOPP 
(bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisolone) followed by 
30 Gy IFRT in all groups. Investigators noted more toxic 
eﬀ ects in patients in the BEACOPP group than in the 
ABVD groups, but outcome did not diﬀ er. The GHSG 
HD11 trial49 randomised patients to get four cycles of either 
ABVD or baseline BEACOPP and either 20 Gy or 30 Gy 
IFRT. The outcome was inferior after ABVD and 20 Gy 
radiotherapy, but other treatment groups had similar 
outcomes, indicating that baseline BEACOPP and 20 Gy 
IFRT is as eﬀ ective as ABVD and 30 Gy IFRT. However, 
because more toxic eﬀ ects were associated with BEACOPP 
than with ABVD, most clinicians have concluded that four 
cycles of ABVD followed by 30 Gy IFRT should remain 
standard practice. To investigate further whether intensive 
chemo therapy can improve outcome in this group, the 
GHSG HD14 trial51 randomly assigned patients to receive 
either four cycles of ABVD or two cycles of escalated 
BEACOPP, followed by two cycles of ABVD with 30 Gy 
IFRT in both treatment groups. A small but signiﬁ cant 
improvement in freedom from treatment failure was 
identiﬁ ed in patients who received escalated BEACOPP 
and two cycles of ABVD compared with those who received 
six cycles of ABVD (94·8% vs 87·7%, p<0·001), but 
grade 3 and 4 toxic eﬀ ects also increased. Therefore, these 
results do not mandate a change in practice.
Management of advanced disease
The standard treatment for advanced-stage disease is 
combination chemotherapy. ABVD has better outcomes 
than do previous regimens such as MOPP (mechlor-
ethamine, vincristine, procarbazine, and prednisolone)
and was equivalent to alternation of MOPP and ABVD 
or a MOPP–ABV hybrid,52,53 or alternation of ChlVPP 
(chlorambucil, vinblastine, procarbazine, and pred-
nisolone) with PABLOE (prednisolone, doxorubicin, 
bleomycin, vincristine, and etoposide).54 ABVD is asso-
ciated with lower rates of pulmonary and haematological 
toxic eﬀ ects, secondary myelodysplasia, leukaemia, and 
infertility than is MOPP–ABV, making it a better 
treatment. ABVD therefore became standard therapy, 
with rates of progression-free survival of about 70% and 
overall survival of 82–90%.53–57 Attempts have been 
made to improve upon these results. The Stanford V 
regimen—a weekly regimen of seven drugs given over 
3 months combined with extensive radiotherapy—was 
initially thought to lead to improved outcome. However, 
ﬁ ndings from a prospective trial55 comparing this regimen 
with six to eight cycles of ABVD in the UK showed no 
diﬀ erence in outcome. Results of an Italian trial58 showed 
that the Stanford V regimen was inferior to ABVD.
In the GHSG HD9 trial,59,60 patients were randomly 
assigned to eight cycles of alternating COPP and ABVD, 
eight cycles of baseline BEACOPP, or eight cycles of 
escalated BEACOPP, with IFRT delivered to sites of initial 
bulk and residual masses after chemotherapy in all groups. 
10 year freedom from treatment failure was 82% and 
overall survival was 86% in the escalated BEACOPP group, 
both of which were signiﬁ cantly better than were results 
associated with either baseline BEACOPP or COPP and 
ABVD (although perhaps ABVD would have been a better 
Panel 2: International prognostic index (Hasenclever 
score) for advanced-stage Hodgkin’s lymphoma17
• Age >45 years
• Male sex
• Serum albumin concentration <40 g/L
• Haemoglobin concentration <105 g/L
• Stage IV disease
• Leucocytosis (≥15×10⁹ white cells per L)
• Lymphopenia (<0·6×10⁹ lymphocytes per L, or <8% total 
white-cell count)
5 year FFP (SE) 5 year OS (SE)
Score 0 84% (4) 89% (2)
Score 1 77% (3) 90% (2)
Score 2 67% (2) 81% (2)
Score 3 60% (3) 78% (3)
Score 4 51% (4) 61% (4)
Score ≥5 42% (5) 56% (5)
FFP= freedom from progression. OS=overall survival. 
Table 3: Reductions in 5 year freedom from progression and overall 
survival relative to score on international prognostic index
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standard comparator than COPP alternated with ABVD). 
Escalated BEACOPP results in increased haematological 
toxic eﬀ ects, infec tions, secondary malignancies, and rates 
of infertility compared with both BEACOPP and alter-
nating COPP–ABVD,60,61 but the improvement in overall 
survival at 10 years is impressive (overall survival at 10 
years was 75% with COPP–ABVD, 80% with baseline 
BEACOPP, and 86% with esclated BEACOPP).
The GHSG HD12 trial62 assessed whether the toxic 
eﬀ ects of BEACOPP can be reduced; four cycles of escal-
ated BEACOPP were followed by four cycles of baseline 
BEACOPP and preliminary results suggest that this 
regimen is not associated with a signiﬁ cant loss in 
eﬃ  cacy. Meanwhile the GHSG HD15 trial63 reported 
better results and fewer toxic eﬀ ects and secondary 
malignancies with six cycles of escalated BEACOPP 
followed by PET-guided radiotherapy than with either 
eight cycles of escalated BEACOPP or eight cycles of 
BEACOPP-14.
Findings from a small Italian trial56 conﬁ rmed that 
event-free survival was better with escalated BEACOPP 
than with ABVD. However, salvage was inferior in 
patients who did not respond to BEACOPP, and thus the 
overall survival beneﬁ t at 7 years was not signiﬁ cant (89% 
with BEACOPP vs 84% with ABVD). The power of this 
trial was low, but a Cochrane analysis64 of four trials of 
escalated BEACOPP (including the Italian study) showed 
that although progression-free survival increases 
signiﬁ cantly with escalated BEACOPP (HR 0·53, 95% CI 
0·44–0·64), this improvement does not translate to a 
signiﬁ cant beneﬁ t in overall survival (0·8, 0·59–1·09). 
Some centres previously reserved escalated BEACOPP 
for patients with high international prognostic scores,65 
but long-term follow-up of the GHSG HD9 trial suggests 
that the regimen has an equivalent beneﬁ t in patients of 
any score.60
The role of radiotherapy in advanced-stage disease 
is unclear. IFRT to sites of initial disease bulk was 
previously given to all patients after chemotherapy, and 
ﬁ ndings from a retrospective analysis66 of data from the 
UK suggested that this strategy improved progression-free 
and overall survival. An EORTC trial67 randomly assigned 
patients in complete remission after MOPP–ABV to IFRT 
or no radiotherapy, and showed no signiﬁ cant diﬀ erences 
in event-free or overall survival between the two groups.67 
In the same study, patients in partial remission after 
chemotherapy beneﬁ ted from consolidation radiotherapy, 
leading the investigators to recommend consolidation 
IFRT only to such patients.68 However, the ﬁ ndings of the 
GHSG HD15 trial showed that radiotherapy can be 
omitted for patients with residual masses if they are PET 
negative after BEACOPP chemotherapy.23 Thus, the 
proportion of patients beneﬁ ting from consolidation 
radiotherapy is probably small.
Randomised trials have established that consolidation 
of ﬁ rst complete remission with high-dose therapy and 
autologous stem-cell transplantation has no beneﬁ t in 
progression-free or overall survival, even in patients 
with high-risk disease.69–71 Thus, this approach is 
not recommended.
Response-adapted therapy
Interim ¹⁸F-FDG PET in advanced-stage disease has high 
sensitivity and speciﬁ city,72 and is better than the 
international prognostic score in prediction of out-
come.25–27 Treatment can be tailored according to the 
results of interim PET scans in advanced disease. Avigdor 
and colleagues65 gave 45 patients two cycles of escalated 
BEACOPP and then did a PET–CT scan. 72% of patients 
had a negative scan, and de-escalation to ABVD for a 
subsequent four cycles led to 4 year progression-free 
survival of 87%. The GHSG HD18 trial73 is testing 
whether the number of cycles of escalated BEACOPP can 
be reduced from eight to four in patients with a negative 
interim scan. An alternative approach is to start treatment 
with ABVD and escalate to BEACOPP if the interim scan 
is positive.74,75 This strategy is being prospectively explored 
in the UK National Cancer Research Institute Response 
Adapted Therapy using FDG-PET Imaging in Advanced 
Hodgkin Lymphoma (RATHL) trial.76 This trial is also 
assessing the randomised omission of further bleomycin 
in patients with a negative ¹⁸F-FDG PET scan after two 
cycles of ABVD.
Relapsed or refractory disease and salvage 
chemotherapy
Roughly 10% of patients with early-stage disease and 
20–30% with advanced disease will be refractory to, 
or relapse after, initial treatment. The strategy for 
management of relapsed or refractory disease is to deliver 
salvage chemotherapy, followed by high-dose chem-
otherapy and autologous stem-cell transplantation in 
responding patients.77,78 The outlook of patients with 
relapsed disease depends on time to relapse, stage at time 
of relapse, and performance status. Patients with 
refractory disease—including those who relapse less 
than 3 months after completion of treatment—have 
signiﬁ cantly worse outcomes than do those who relapse 
having previously been in remission.79 In large German 
retrospective studies, 5 year overall survival for primary 
Panel 3: Deauville criteria for interim 
¹⁸F-ﬂ uorodeoxyglucose PET29
1 No uptake
2 Uptake ≤mediastinum
3 Uptake >mediastinum but ≤liver*
4 Uptake moderately increased at any site compared with 
the liver
5 Uptake substantially increased at any site compared with 
the liver, or any new sites of disease
*Score 3 could be judged positive in trials investigating a reduction in therapy, or 
negative in trials investigating intensiﬁ cation of treatment.
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refractory patients was 26%,80 compared with 46% for 
those relapsing 3–12 months after chemotherapy and 71% 
for those relapsing more than 1 year after treatment.81
No trials have directly compared salvage regimens or 
investigated the optimum number of cycles. Salvage 
chemotherapy should ideally introduce drugs that were 
not used in the original treatment, should be reasonably 
non-toxic, and should not impair subsequent harvest 
of haemopoietic stem cells.79 ESHAP (etoposide, 
methylprednisolone, cytarabine, and cisplatin), DHAP 
(dexamethasone, cytarabine, and cisplatin), IVE 
(ifospha mide, etoposide, and epirubicin), and ICE 
(ifosphamide, carboplatin, and etoposide) are the most 
widely used, with response rates of 60–80%.79 BEACOPP 
has also been successfully used in this setting.82 
Radiotherapy alone could have a role in selected patients 
with localised late relapse, but the criteria for this 
situation are hard to deﬁ ne.83
For patients not responding to ﬁ rst-line salvage 
chemotherapy, an alternative salvage regimen such as 
mini-BEAM (carmustine, etoposide, cytarabine, and 
melphalan) can be eﬀ ective as a bridge to transplantation 
in many patients. The new drug brentuximab vedotin 
could be useful in this context. A UK prospective trial84 is 
investigating the role of allogeneic haemopoietic stem-cell 
transplantation in the primary refractory setting.
Stem-cell transplantation
Autologous stem-cell transplantation
Data from randomised trials77,78 show improved 
progression-free survival with salvage chemotherapy 
followed by autologous stem-cell transplantation com-
pared with salvage chemotherapy alone. Reﬁ ne ments in 
techniques, including use of peripheral-blood stem cells 
and growth factors and improved patient selection and 
supportive care, have led to a reduction in transplantation-
related mortality to less than 3%. The depth of response 
(ie, complete response vs partial response) to salvage 
chemotherapy before autologous stem-cell transplantation 
is important, with improved progression-free and overall 
survival for patients in complete remission,85 and evidence 
shows that a negative ¹⁸F-FDG PET scan after salvage 
chemotherapy predicts outcome after autologous stem-
cell trans plantation.86 Overall survival in patients with 
relapsed disease treated with this technique is greater 
than 65%, compared with 30% in refractory disease.87
Use of sequential high-dose therapy to increase the 
intensity of conditioning before autologous stem-cell 
transplantation has no obvious beneﬁ t compared with 
the standard BEAM (carmustine, etoposide, cytarabine, 
and melphalan) regimen and autologous stem-cell 
transplantation, and is associated with increased toxic 
eﬀ ects.88 Similarly, intensiﬁ cation with tandem autolo-
gous stem-cell transplantation has been inves tigated 
and could have a role in patients with adverse risk 
factors, although any potential beneﬁ t should be 
weighed against the increased toxic eﬀ ects.89
Allogeneic haemopoietic stem-cell transplantation
Evidence of a graft-versus-disease eﬀ ect in Hodgkin’s 
lymphoma90 has resulted in increased use of reduced-
intensity conditioning allogeneic transplantation in 
patients who did not respond to standard salvage 
therapy; treatment-related mortality of this procedure in 
expert centres is roughly 20%.91,92 Use of donor 
lymphocyte infusions to harness the graft-versus-disease 
eﬀ ect and treat relapse after transplantation has also 
been shown.91 In a donor versus no-donor analysis of 
patients who relapsed after autologous stem-cell 
transplantation, both progression-free (39·3% vs 14·2%) 
and overall survival (66% vs 42%) were signiﬁ cantly 
higher in the donor group than in the no-donor group 
(p<0·001).93 Allogeneic transplantation might also be 
beneﬁ cial in selected high-risk patients who have not 
had autologous stem-cell transplantation, but precise 
indications are controversial.
New drugs
For patients who relapse after or are unsuitable for 
allogeneic haemopoietic stem-cell transplantation, treat-
ment is either palliative or experimental. Single-drug 
chemotherapy with gemcitabine or vinblastine has been 
used in this setting, with gemcitabine providing an 
overall response rate of 39% with a median duration of 
response of 6 months.94 Although Hodgkin and Reed–
Sternberg cells are not usually CD20 positive, responses 
to rituximab used either alone or in combination with 
chemotherapy in relapsed disease have been reported.95 
Rituximab in combination with chemotherapy in the 
ﬁ rst-line setting is being assessed in a GHSG trial 
(clinicaltrials.gov registration number NCT00515554).
Remarkable response rates in relapsed or refractory 
disease have been achieved in early phase trials with 
brentuximab vedotin, an anti-CD30 antibody conjugated 
to an antimicrotubule drug. In a phase 1 trial of heavily 
pretreated patients with a median of three previous lines 
of treatment, the overall response rate was 86% (the rate 
of complete remission was 25%).96 Impressive rates of 
control were also noted in a multicentre phase 2 trial of 
patients with a median of four lines of previous therapy 
who relapsed after autologous stem-cell transplantation. 
The initial results—published in abstract form, with 
short median follow-up—show an overall response rate 
of 75% and complete remission in 34% of patients.97,98 
This drug thus shows great promise for disease control 
in patients with refractory disease or multiple relapses 
as a bridge to transplantation, and might have a role in 
earlier stages of the disease.
Other drugs that have shown activity in early-phase 
trials in relapsed disease include the immuno -
modulatory agent lenalidomide,99 the mammalian 
target of rapamycin inhibitor everolimus,100 and the 
pandeacetylase inhibitor panobinostat.101 Bortezomib (a 
proteasome inhibitor) has poor activity when used alone, 
but could have a role in combination with other drugs.102
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Nodular lymphocyte-predominant Hodgkin’s 
lymphoma
Nodular lymphocyte-predominant Hodgkin’s lymphoma 
accounts for 5% of all Hodgkin’s lymphoma diagnoses 
and is distinguished from classical disease by the 
absence of Hodgkin and Reed–Sternberg cells and the 
presence of characteristic lymphocyte-predominant 
cells, which are sometimes called popcorn cells.8 
Lymphocyte-predominant cells are clonal B cells that 
have retained the B-cell phenotype and are classically 
CD30 negative.8 Most patients (70%) are male and 
median age at presentation is 30–40 years. Early-stage 
disease is identiﬁ ed in 75% of patients.103 Nodular 
lymphocyte-predominant Hodgkin’s lymphoma has an 
excellent prognosis, but late relapses are frequently 
recorded.104 Transformation to diﬀ use large B-cell 
lymphoma is reported in 8–14% of patients 4–8 years 
after diagnosis,104–106 and the risk of transformation 
increases with time.105
Because of the rarity of nodular lymphocyte-
predominant Hodgkin’s lymphoma, few prospective 
trial data are available, and the best treatment is 
unknown. In view of the excellent long-term survival 
and young age at presentation, the late eﬀ ects of 
treatment should be carefully considered. For patients 
who have had an excision biopsy taken and have 
no evidence of residual disease, some clinicians 
have previously used observation alone, but this strategy 
could be unacceptable because of the high rate of 
relapse.106,107 Early-stage disease can be treated with 
radiotherapy alone, leading to 10 year progression-free 
survival of 89% and overall survival of 96%; the rate of 
relapse is higher in stage 2 than in stage 1 disease, but 
overall survival does not diﬀ er.108 IFRT is as eﬀ ective as 
more extensive radio therapy and has lower rates of 
late complications. In advanced disease, combination 
chemo therapy is needed, but little evi dence is available 
to support a particular regimen. ABVD is often used, but 
regimens with fewer toxic eﬀ ects such as CVP (cyclo-
phosphamide, vincristine, and prednisolone) are recom-
mended by some groups.43 Rituximab has been used as a 
single agent in phase 2 trials in both front-line and 
relapsed settings, with response rates of up to 100% but 
frequent relapses.109,110 The incorporation of rituximab 
into chemotherapy regimens might be reasonable, and 
rituximab main tenance might also be beneﬁ cial, 
although this practice is not proven.
Special situations
Elderly
Elderly patients have poorer survival than do younger 
patients because of comorbidities, toxic eﬀ ects of treat-
ment, and reduced treatment intensity. In the absence of 
comorbidities precluding anthracycline use, standard 
treatment is recommended in patients younger than 
70 years. For elderly patients or those with note worthy 
comorbidities, ABVD is thought to be too toxic, and 
alternative regimens such as VEPEMB (vinblastine, 
cyclophosphamide, procarbazine, prednisolone, etopo-
side, mitoxantrone, and bleomycin) are used.111,112 New 
drugs with few toxic eﬀ ects will probably have a role in the 
treatment of elderly patients with Hodgkin’s lymphoma.
Pregnancy
Hodgkin’s lymphoma is one of the most common cancers 
reported in pregnancy.113 To avoid radiation exposure, 
staging should be with ultrasonography or whole-body 
MRI.114 Radiotherapy should generally be avoided because 
of the risk of teratogenicity. On the basis of data from 
small case series, treatment with ABVD seems to be safe, 
especially in the second and third trimesters.115 Other 
treatment options include observation or symptom 
control with steroids or vinblastine alone until delivery. 
However, the potential increased risk of relapse or 
refractory disease with this approach should be considered.
HIV/AIDS
In the era of highly active antiretroviral therapy, the 
management and disease-speciﬁ c prognosis of patients 
with coexisting HIV/AIDS and Hodgkin’s lymphoma are 
the same as for patients with Hodgkin’s lymphoma 
without HIV/AIDS.116,117
Late eﬀ ects of treatment and survivorship
The late eﬀ ects of treatment are key determinants of 
the long-term morbidity, mortality, and quality of life of 
patients treated for Hodgkin’s lymphoma and neces sitates 
long-term follow-up. In the ﬁ rst 10 years after treatment 
most deaths are due to relapse, but after this time deaths 
due to late eﬀ ects predominate.118 Secondary malignancies 
can be solid organ (most commonly lung, skin, breast, and 
gastrointestinal) or haematological (leukaemia, myelo -
dysplasia, and secondary lymph omas).119 Risk of secondary 
malignancies is highest after treatment in childhood.120,121 
Radiotherapy is associated with increased cancer risk at 
most irradiated sites, whereas after chemotherapy secon-
dary malignancies are restricted to acute leukaemia, non-
Hodgkin lymphoma, and lung cancer.122 Initial treatment 
with radiotherapy alone has the highest risk of secondary 
malignancies because of treatment failures and exposure 
to subse quent salvage therapy.123,124 The risk of development 
of malignant disease in people treated for Hodgkin’s 
lymphoma before adulthood has been estimated to be 
18·5 times greater than the general population, with a 
30 year cumulative risk of 18% for male patients and 26% 
for female patients.121
The most common secondary malignancy in female 
patients is breast cancer. Age of younger than 20 years 
at time of treatment and EFRT incorporating the 
mediastinum are the most important risk factors.124,125 The 
risk of breast cancer was estimated to be 29% (95% CI 
20·2–40·1%) in patients who received 40 Gy mediastinal 
irradiation before age 25 years in one study.126 UK 
guidelines recommend that female patients given 
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supradiaphragmatic radiotherapy are oﬀ ered screening 
with yearly mammography or MRI from 8 years after 
treatment or at age 25 years (whichever is later).127 US 
guidelines recommend yearly screening from 10 years 
after treatment or at 40 years of age (whichever is earlier).43
Chemotherapy drugs, especially alkylating agents, 
contribute to secondary malignancy risk; however, the 
increase in risk associated with ABVD seems negligible. 
Small increases in the incidence of myelodysplasia and 
acute myeloid leukaemia were reported in the BEACOPP 
groups of the GHSG HD9 trial, although the overall rate 
of secondary malignant disease was not increased 
compared with other chemotherapy regimens.60
Increases in incidence (noted from 1 to more than 
25 years after therapy) of myocardial infarction, con-
gestive cardiac failure, asymptomatic coronary disease, 
valvular dysfunction, and stroke have all been recorded 
after treatment for Hodgkin’s lymphoma, and the risk of 
cardiac mortality persists for many years after treatment.128 
The risk is related to supradiaphragmatic radiotherapy, 
anthra cycline-containing chemotherapy, and possibly the 
use of vinca alkaloids. Traditional cardiovascular risk 
factors are additive and adjustment of modiﬁ able risk 
factors is important.
Other late eﬀ ects include subfertility, endocrine dys-
function, peripheral neuropathy, and local eﬀ ects from 
radiotherapy. Fertility is an important consideration in 
view of the young age of many people diagnosed with 
Hodgkin’s lymphoma. Rates of amenorrhoea are 
higher, whereas recovery of antimüllerian hormone 
concentrations and birth rates are lower, in women 
given BEACOPP than in those given ABVD; being older 
than 30 years at time of treatment was an important 
risk factor for subfertility.129 In one study,130 50% of women 
given escalated BEACOPP did not recover normal 
menstruation compared with less than 5% after ABVD. 
Attempts to protect female fertility during BEACOPP 
treatment by hormonal manipulation have been 
unsuccessful.131 Pregnancy is frequently possible after 
autologous stem-cell transplantation if menstruation was 
normal before high-dose therapy. In men, the rate of 
azoospermia after treatment with BEACOPP is 87–93%, 
whereas ABVD induces permanent azoosepermia in less 
than 5% of patients.61,132,133 For male patients, sperm storage 
can usually be oﬀ ered before treatment, whereas fertility-
sparing measures in female patients are time consuming 
and, because of treatment delays, not always advisable.
Conclusion
Today most patients with Hodgkin’s lymphoma are cured 
and current developments are likely to lead to further,  if 
small, improvements in overall survival because of both 
improved tumour eradication and reduction of late 
eﬀ ects. Because of the success of the treatment of 
Hodgkin’s lymphoma, proof of further advances will 
require very large trials with long-term follow-up, and 
international collaboration will be essential.
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